Equillium’s phase 3 graft-versus-host disease (GVHD) trial has missed its primary endpoint and two key secondary objectives.

Ionis Pharmaceuticals (IONS) announced that it has entered into a license agreement under which Sobi received exclusive rights in countries ...

Below, check out the roundup of California Healthline’s coverage. For today's national health news, read KFF Health News’ Morning Briefing.

Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine ...

Small-molecule inhibitors targeting viral proteins could serve as an effective alternative for controlling the spread of COVID-19 at both individual and community levels. In this vein, a recent study ...

Shaya Fainman, a distinguished professor at UC San Diego, has spent over 40 years advancing photonics research. From ...

As the trend towards the international dispersion of certain value chain activities produces challenges, discover policies to meet these Tax transparency and international co-operation Enhanced ...

Irelands economic growth is expected to slow in 2024 as global risks mount, posing a significant challenge to its multinational-driven economy, the countrys central bank warned. The bank revised its ...

Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...